S&P 500
5,939.30
-0.5%
-$31.51
DJI
42,319.74
-0.3%
-$108.00
NASDAQ
19,298.45
-0.8%
-$162.04
Bitcoin
103,684.00
-0.9%
-978.64
AAPL
$200.39
-1.2%
-$2.43
AMZN
$207.76
+0.3%
+$0.53
GOOG
$169.74
+0.2%
+$0.35
META
$683.71
-0.6%
-$4.24
MSFT
$467.07
+0.7%
+$3.20
NVDA
$139.88
-1.4%
-$2.04
TSLA
$285.20
-14.1%
-$46.85
Tourmaline Bio (NASDAQ: TRML)
$18.89
(0.9%)
$0.16
Price as of June 5, 2025, 4:00 p.m. ET
Tourmaline Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Tourmaline Bio Company Info
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. The firm offers TOUR006, an anti-IL-6 antibody that exhibits differentiated properties including high binding affinity to IL-6 and a naturally long half-life. It also plans to develop TOUR006 in thyroid eye disease and atherosclerotic cardiovascular disease. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.